octanedioic acid [4-(1-benzyl-1H-[1,2,3]triazol-4-yl)phenyl]amide hydroxyamide | 1033390-82-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: octanedioic acid [4-(1-benzyl-1H-[1,2,3]triazol-4-yl)phenyl]amide hydroxyamide
• 英文别名: Triazole Ligand, 6a；N-[4-(1-benzyltriazol-4-yl)phenyl]-N'-hydroxyoctanediamide
• CAS: 1033390-82-7
• 化学式: C₂₃H₂₇N₅O₃
• 分子量: 421.499
• InChiKey: VPPFVJQPLWFTFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  7-[4-(1-benzyl-1H-[1,2,3]triazol-4-yl)phenylcarbamoyl]heptanoic acid methyl ester 在 氢氧化钾 、 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以43%的产率得到octanedioic acid [4-(1-benzyl-1H-[1,2,3]triazol-4-yl)phenyl]amide hydroxyamide
  参考文献：
  名称：

  A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and Plasmodium falciparum

  摘要：

  The discovery of the rules governing the inhibition of the various HDAC isoforms is likely to be key to identifying improved therapeutics that act as epigenetic modulators of gene transcription. Herein we present results on the modification of the CAP region of a set of triazolylphenyl-based HDACIs, and show that the nature of substitution on the phenyl ring plays a role in their selectivity for HDAC1 versus HDAC6, with low to moderate selectivity (2-51-fold) being achieved. In light of the valuable selectivity and potency that were identified for the triazolylphenyl ligand 6b in the inhibition of HDAC6 (IC50 = 1.9 nM), this compound represents a valuable research tool and a candidate for further chemical modifications. Lastly, these new HDACIs were studied for both their anticancer and antimalarial activity, which serve to validate the superior activity of the HDACI 10c.

  DOI：

  10.1021/jm701606b

文献信息

• HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF
  申请人：The George Washington University, A Congressionally Chartered Not-for-Profit Corporation

  公开号：US20220401474A1

  公开（公告）日：2022-12-22

  The present disclosure provides histone deacetylase 6 (HDAC6)-activated macrophages, compositions comprising HDAC6-activated macrophages, methods of making HDAC6-activated macrophages, and methods of treating diseases, e.g., cancer, by administering a therapeutically effective amount of HDAC6-activated macrophages.
• [EN] STAT-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF<br/>[FR] MACROPHAGES ACTIVÉS PAR STAT, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：[en]THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION

  公开号：WO2022094319A1

  公开（公告）日：2022-05-05

  The present disclosure provides signal transducer and activator of transcription (STAT)-activated macrophages, compositions comprising STAT-activated macrophages, methods of making STAT-activated macrophages, and methods of treating diseases, e.g., cancer, by administering a therapeutically effective amount of STAT-activated macrophages.
• A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and <i>Plasmodium falciparum</i>
  作者：Yufeng Chen、Miriam Lopez-Sanchez、Doris N. Savoy、Daniel D. Billadeau、Geoffrey S. Dow、Alan P. Kozikowski

  DOI：10.1021/jm701606b

  日期：2008.6.1

  The discovery of the rules governing the inhibition of the various HDAC isoforms is likely to be key to identifying improved therapeutics that act as epigenetic modulators of gene transcription. Herein we present results on the modification of the CAP region of a set of triazolylphenyl-based HDACIs, and show that the nature of substitution on the phenyl ring plays a role in their selectivity for HDAC1 versus HDAC6, with low to moderate selectivity (2-51-fold) being achieved. In light of the valuable selectivity and potency that were identified for the triazolylphenyl ligand 6b in the inhibition of HDAC6 (IC50 = 1.9 nM), this compound represents a valuable research tool and a candidate for further chemical modifications. Lastly, these new HDACIs were studied for both their anticancer and antimalarial activity, which serve to validate the superior activity of the HDACI 10c.